Major Depressive Disorder Market

Market Overview: 

The top 7 major depressive disorder markets reached a value of US$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.1 Billion by 2034, exhibiting a growth rate (CAGR) of 1.88% during 2024-2034.

The major depressive disorder market has been comprehensively analyzed in IMARC's new report titled "Major Depressive Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Major depressive disorder, also referred to as clinical depression, is a mental condition that causes alterations in brain function, including the disrupted activity of specific neural circuits in the brain. The disease is characterized by at least two weeks of pervasive low mood, loss of interest or pleasure in normally enjoyable activities, and lack of self-esteem. The common symptoms of this condition include inappropriate guilt or regret, feelings of worthlessness, helplessness, poor concentration, reduced sex drive, withdrawal from social situations and activities, irritability, suicidal thoughts, etc. Additionally, individuals suffering from major depressive disorder may experience insomnia, hypersomnia, oversleeping, fatigue, headaches, or digestive problems. Diagnosing this ailment is based on the patient's symptoms, biographical history, and mental status examination. The healthcare provider also performs cognitive tests and brain imaging studies to help distinguish depression from other mental disorders. Various assessment tools, such as the Hamilton Rating Scale for Depression and the Beck Depression Inventory, are utilized to determine the severity of symptoms and confirm a diagnosis.

The rising incidences of several associated risk factors, including stressful life events, medical conditions like chronic illness, psychological factors such as personality traits, etc., are primarily driving the major depressive disorder market. In addition to this, the increasing cases of imbalances in brain chemistry, specifically in the levels of certain neurotransmitters, are also propelling the market growth. Furthermore, the inflating adoption of effective medications, including antidepressants and anxiolytics, to improve mood and reduce symptoms of depression is acting as another significant growth-inducing factor. Apart from this, the escalating application of transcranial magnetic stimulation, a noninvasive treatment procedure that utilizes magnetic fields to stimulate brain nerve cells and alleviate disease indications, is further creating a positive outlook for the market. Moreover, the widespread demand for behavioral interventions, such as interpersonal and cognitive-behavioral therapies, to prevent new-onset depression and change unhealthy thoughts, emotions, and behaviors is also augmenting the market growth. Additionally, the emerging popularity of low-dose psychedelic drugs that boost the activity of glutamate in the brain and improve the patient's mood is expected to drive the major depressive disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the major depressive disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for major depressive disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the major depressive disorder market in any manner.

Recent Developments:

• In April 2024, Neurocrine Biosciences, Inc. revealed positive topline results from its Phase 2 SAVITRI study. This randomized, double-blind, placebo-controlled dose-finding research evaluated the efficacy and safety of NBI-1065845 in adult patients with major depressive disorder.
• In January 2024, Saniona disclosed the selection of its innovative GABAA α5 Negative Allosteric Modulator (NAM) lead chemical, SAN2465, as a clinical candidate for major depressive disorder. SAN2465 effectively reversed chronic stress-induced depression symptoms such as anhedonia, anxiety, and cognitive impairment.
• In September 2023, Relmada Therapeutics, Inc. reported efficacy data for de novo (or new to therapy) patients (204 patients) and safety results for all subjects (627 patients) in the Phase 3 long-term, open-label, registrational trial (Study 310) of REL-1017 in patients with major depressive disorder. Patients who received REL-1017 daily for up to a year experienced fast, clinically substantial, and long-term reductions in depression symptoms and associated functional impairment.
• In September 2023, Small Pharma Inc. announced favorable safety, tolerability, and efficacy results from its Phase Ib study of the interaction of selective serotonin reuptake inhibitors (SSRIs) with SPL026, native N, N-dimethyltryptamine (DMT) in patients with major depressive disorder.
• In February 2023, Biogen Inc. and Sage Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) had accepted their New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder. Zuranolone is an investigational medication that is being tested as a 14-day, once-daily oral therapy for individuals with major depressive disorder.

Key Highlights:

• Major depressive disorder has a lifetime prevalence of 5–17 percent, with an average of 12 percent.
• The National Institute of Mental Health estimates that 8.3% of the US population (21.0 million people) have experienced a major depressive episode.
• The prevalence rate of this disorder is about double in women than in men.
• Though the average age of onset is around 40 years, new surveys reveal that the incidence is increasing in the younger population as a result of alcohol and other substance usage.
• Low income was revealed to be a significant risk factor for major depressive disorder in those under the age of 65.

Drugs:

Auvelity is a new N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity that is approved for the treatment of major depressive disorder in adults. Auvelity, developed by the US-based biopharmaceutical company Axsome Therapeutics, is an extended-release oral tablet containing 45mg dextromethorphan HBr and 105mg bupropion HCl.

Ulotaront hydrochloride (SEP-363856) is being developed for the treatment of major depressive disorder. The medication candidate is delivered orally. It is an antipsychotic medication. It works by targeting the TAAR1 and serotonin 5-HT1A receptors.

Zuranolone (SAGE-217) is an experimental medication under development for the treatment of major depressive disorder that is administered once a day for 14 days. Zuranolone is an oral neuroactive steroid (NAS) that acts as a positive allosteric modulator of GABA-A receptors. The GABA system is the primary inhibitory signaling channel in the brain and central nervous system, and it helps to regulate brain function.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the major depressive disorder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the major depressive disorder market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current major depressive disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the major depressive disorder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the major depressive disorder market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the major depressive disorder market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of major depressive disorder across the seven major markets?
• What is the number of prevalent cases (2018-2034) of major depressive disorder by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of major depressive disorder by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with major depressive disorder across the seven major markets?
• What is the size of the major depressive disorder patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of major depressive disorder?
• What will be the growth rate of patients across the seven major markets?
   

Major Depressive Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for major depressive disorder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the major depressive disorder market?
• What are the key regulatory events related to the major depressive disorder market?
• What is the structure of clinical trial landscape by status related to the major depressive disorder market?
• What is the structure of clinical trial landscape by phase related to the major depressive disorder market?
• What is the structure of clinical trial landscape by route of administration related to the major depressive disorder market?